Utrobin 5 - Tablet Solifenacin Succinate - 5mg 10 Tablet(s) / Strip Unimed Unihealth Pharmaceuticals Ltd. Introduction: Utrobin 5 is a muscarinic antagonist that is used in the treatment of overactive bladder. It relieves urinary symptoms like frequent urination, urgent need to urinate and inability to control urination. Utrobin 5 is advised to take it in a dose and duration as per prescription. It can be taken with or without food. Swallow the medicine as a whole without crushing or chewing it. You should not stop taking the medicine without consulting the doctor as it may lead to the worsening of your symptoms. The course of the treatment should be completed for better efficacy of the medicine.... Uses of Utrobin 5: Overactive bladder (OAB) symptoms Side effects of Utrobin 5: Dryness in mouthConstipationBlurred visionNauseaUpset stomachUrinary tract infection How to use Utrobin 5: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Utrobin 5 may be taken with or without food, but it is better to take it at a fixed time. How Utrobin 5 works: Utrobin 5 is an antimuscarinic. It works by relaxing muscles of the urinary bladder to prevent frequent, urgent or uncontrolled urination. What if you forget to take Utrobin 5?: If you miss a dose of Utrobin 5, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Overactive bladder Administration: May be taken with or without food. Swallow whole, do not chew/crush. Adult Dose: Oral Overactive bladder Adult: 5 mg once daily. If well tolerated, may increase to 10 mg once daily if needed. For patients who are concurrently taking CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max dose: 5 mg once daily. Hepatic impairment: Child-pugh class B: Max: 5 mg daily; Child-pugh class C: Use is not recommended. Renal Dose: Renal impairment: CrCl (ml/min) Dosage Recommendation <30 Max: 5 mg daily. Contraindication: Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention. Mode of Action: Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure. Precaution: Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation. Side Effect: Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza. Interaction: May interfere with the prokinetic effects of cisapride and metoclopramide. Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.